ARTICLE | Clinical News
ZYN002: Phase II started
July 18, 2016 7:00 AM UTC
Zynerba began the double-blind, placebo-controlled, Australian Phase II STAR 1 trial to evaluate 97.5 and 195 mg transdermal ZYN002 twice daily for 12 weeks in about 180 adult patients. ...